Design and Evaluation of Pyrimidine Derivatives As Potent Inhibitors of ABCG2, a Breast Cancer Resistance Protein

Overview

Journal 3 Biotech

Publisher Springer

Specialty Biotechnology

Date 2022 Jul 25

PMID 35875174

Authors

Shahnawaz Ahmad

Md Imtaiyaz Hassan

Dinesh Gupta

Neeraj Dwivedi

Asimul Islam

Affiliations

Soon will be listed here.

Abstract

Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-022-03231-1.

Citing Articles

Computer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors.

Faris A, Ibrahim I, Al Kamaly O, Saleh A, Elhallaoui M Molecules. 2023; 28(15).

PMID: 37570884 PMC: 10473238. DOI: 10.3390/molecules28155914.

Circular Sponge against miR-21 Enhances the Antitumor Activity of Doxorubicin against Breast Cancer Cells.

Rama A, Lara P, Mesas C, Quinonero F, Velez C, Melguizo C Int J Mol Sci. 2022; 23(23).

PMID: 36499129 PMC: 9736351. DOI: 10.3390/ijms232314803.

References

Krapf M, Gallus J, Wiese M . 4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2). J Med Chem. 2017; 60(10):4474-4495. DOI: 10.1021/acs.jmedchem.7b00441. View

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell H, Ibrahim-Hashim A . Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73(5):1524-35. PMC: 3594450. DOI: 10.1158/0008-5472.CAN-12-2796. View

Dean M, Hamon Y, Chimini G . The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001; 42(7):1007-17. View

Bento A, Gaulton A, Hersey A, Bellis L, Chambers J, Davies M . The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2013; 42(Database issue):D1083-90. PMC: 3965067. DOI: 10.1093/nar/gkt1031. View

Katari S, Natarajan P, Swargam S, Kanipakam H, Pasala C, Umamaheswari A . Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations. J Recept Signal Transduct Res. 2016; 36(6):558-571. DOI: 10.3109/10799893.2016.1141955. View

Khunweeraphong N, Stockner T, Kuchler K . The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion. Sci Rep. 2017; 7(1):13767. PMC: 5653816. DOI: 10.1038/s41598-017-11794-w. View

Kusuhara H, Sugiyama Y . ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch. 2006; 453(5):735-44. DOI: 10.1007/s00424-006-0134-x. View

Ejendal K, Hrycyna C . Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci. 2002; 3(5):503-11. DOI: 10.2174/1389203023380521. View

Krapf M, Gallus J, Vahdati S, Wiese M . New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold. J Med Chem. 2018; 61(8):3389-3408. DOI: 10.1021/acs.jmedchem.7b01012. View

10.

Ahamad S, Hassan M, Dwivedi N . Designing of phenol-based inhibitors through QSAR, molecular docking, and MD simulation approach. 3 Biotech. 2018; 8(5):256. PMC: 5950840. DOI: 10.1007/s13205-018-1278-z. View

11.

Jackson S, Manolaridis I, Kowal J, Zechner M, Taylor N, Bause M . Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat Struct Mol Biol. 2018; 25(4):333-340. DOI: 10.1038/s41594-018-0049-1. View

12.

Silbermann K, Stefan S, Elshawadfy R, Namasivayam V, Wiese M . Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach. J Med Chem. 2019; 62(9):4383-4400. DOI: 10.1021/acs.jmedchem.8b01821. View

13.

Sharma R . Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018. Breast Cancer Res Treat. 2021; 187(2):557-567. DOI: 10.1007/s10549-020-06083-6. View

14.

Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C . Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2015; 370(1):153-64. DOI: 10.1016/j.canlet.2015.10.010. View

15.

Silbermann K, Li J, Namasivayam V, Baltes F, Bendas G, Stefan S . Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists. J Med Chem. 2020; 63(18):10412-10432. DOI: 10.1021/acs.jmedchem.0c00961. View

16.

Bhardwaj B, Baidya A, Amin S, Adhikari N, Jha T, Gayen S . Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer. SAR QSAR Environ Res. 2019; 30(7):457-475. DOI: 10.1080/1062936X.2019.1615545. View

17.

Kanipakam H, Sharma K, Thinlas T, Mohammad G, Pasha M . Structural and functional alterations of nitric oxide synthase 3 due to missense variants associate with high-altitude pulmonary edema through dynamic study. J Biomol Struct Dyn. 2020; 39(1):294-309. DOI: 10.1080/07391102.2019.1711190. View

18.

Neves B, Braga R, Melo-Filho C, Moreira-Filho J, Muratov E, Andrade C . QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery. Front Pharmacol. 2018; 9:1275. PMC: 6262347. DOI: 10.3389/fphar.2018.01275. View

19.

Hassel B, Doyle L, Ross D . Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta. 2001; 1520(3):234-41. DOI: 10.1016/s0167-4781(01)00270-6. View

20.

Silbermann K, Li J, Namasivayam V, Stefan S, Wiese M . Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site. Eur J Med Chem. 2021; 212:113045. DOI: 10.1016/j.ejmech.2020.113045. View